Posts by Peter W. PENG

In the era of precision medicine for prostate cancer, individualized clinical decision-making has become a central focus of daily practice. At a recent academic conference on urologic oncology, Professor Hailiang Zhang from Huadong Hospital affiliated with Fudan University shared his clinical perspectives on novel hormonal therapy (NHT) in metastatic prostate cancer. He emphasized that, based on solid evidence from randomized clinical trials, NHT combined with androgen deprivation therapy (ADT) has become the standard first-line treatment for both metastatic hormone-sensitive prostate cancer (mHSPC) and metastatic castration-resistant prostate cancer (mCRPC). Nevertheless, optimal treatment selection requires an integrated assessment of tumor burden, genomic characteristics, patient age, and comorbidities, enabling a truly “tailor-made” approach.

Advancing Long-Term Survival Strategies in Urologic Malignancies Highlights from the 15th Shanghai Urologic Oncology Academic Conference Editor’s Note: On December 12, 2025, the 15th Shanghai Urologic Oncology Academic Conference officially…

15th Shanghai Urologic Oncology Academic Conference Editor’s Note: Hosted by the Shanghai Anti-Cancer Association and jointly organized by the Urologic Oncology Committee of the Shanghai Anti-Cancer Association and Fudan University…